Suppr超能文献

1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)在大鼠中发挥厌食作用,该作用可被5-羟色胺2拮抗剂阻断。

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats.

作者信息

Schechter L E, Simansky K J

机构信息

Department of Pharmacology, Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129.

出版信息

Psychopharmacology (Berl). 1988;94(3):342-6. doi: 10.1007/BF00174687.

Abstract

Previous literature suggests that the anorexic action of peripherally administered serotonin (5-HT) is mediated by 5-HT2 receptors. This study, therefore, examined the effect of DOI, a non-indole 5-HT2 agonist, on deprivation-induced feeding. Rats were first adapted to a schedule in which a milk diet was presented for 6 h daily. Intraperitoneal (IP) administration of DOI (1.0-11.2 mumol/kg) inhibited feeding in a dose-related fashion (ID50 = 2.6 mumol/kg). One hour pretreatment with 6.0 mumol/kg of the 5-HT2 antagonists ketanserin and LY53857 completely reversed the anorexic action of an equimolar dose of DOI. Neither ketanserin nor LY53857, alone, altered baseline feeding. Further testing demonstrated the antagonistic effect of LY53857 (0.047-6.0 mumol/kg, IP) to be dose related, with an ID50 of 0.14 mumol/kg. Ten minute pretreatment with 1-(1-naphthyl)-piperazine (1-NP; 2.0 or 4.0 mumol/kg), a mixed-acting agent with 5HT2 blocking actions, also attenuated the anorexic effect of 6.0 mumol/kg DOI. Unlike ketanserin and LY53857, however, 1-NP did reduce food intake by itself. By contrast with ketanserin, LY53857 and 1-NP, the peripherally-acting 5-HT2 antagonist xylamidine failed to alter the anorexic effect of DOI. Taken together, these results suggest that central 5-HT2 receptors are important in the control of ingestive behavior.

摘要

以往的文献表明,外周给予的血清素(5-羟色胺,5-HT)的厌食作用是由5-HT2受体介导的。因此,本研究检测了非吲哚类5-HT2激动剂DOI对禁食诱导进食的影响。首先使大鼠适应每天提供6小时乳类食物的进食计划。腹腔注射DOI(1.0 - 11.2 μmol/kg)以剂量相关的方式抑制进食(半数抑制剂量ID50 = 2.6 μmol/kg)。用6.0 μmol/kg的5-HT2拮抗剂酮色林和LY53857预处理1小时,可完全逆转等摩尔剂量DOI的厌食作用。单独使用酮色林或LY53857均未改变基础进食量。进一步的试验表明,LY5F3857(0.047 - 6.0 μmol/kg,腹腔注射)的拮抗作用呈剂量相关,ID50为0.14 μmol/kg。用具有5-HT2阻断作用的混合作用剂1-(1-萘基)哌嗪(1-NP;2.0或4.0 μmol/kg)预处理10分钟,也可减弱6.0 μmol/kg DOI的厌食作用。然而,与酮色林和LY53857不同,1-NP本身确实会减少食物摄入量。与酮色林、LY53857和1-NP相反,外周作用的5-HT2拮抗剂赛拉米定未能改变DOI的厌食作用。综上所述,这些结果表明中枢5-HT2受体在摄食行为的控制中起重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验